PD 360324 / Pfizer 
Welcome,         Profile    Billing    Logout  

1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PD 360324 / Pfizer
JAVELIN Medley, NCT02554812 / 2015-002552-27: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies

Calendar Jan 2024 - Dec 2024: From JAVELIN Medley trial in combination with utomilumab for NSCLC, melanoma and SCCHN
Checkmark JAVELIN Medley trial of Bavencio + PF-04518600 + utomilumab in advanced malignancies
Jan 2018 - Jan 2018: JAVELIN Medley trial of Bavencio + PF-04518600 + utomilumab in advanced malignancies
Checkmark Combination study with PF-05082566 for NSCLC
Sep 2015 - Sep 2015: Combination study with PF-05082566 for NSCLC
Terminated
1b/2
409
Europe, Canada, Japan, US, RoW
Avelumab, MSB0010718C, Utomilumab, PF-05082566, PF-04518600, PD 0360324, CMP-001
Pfizer
Advanced Cancer
03/23
03/23

Download Options